Japan approves dexamethasone as coronavirus treatment

Japan approves dexamethasone as coronavirus treatment

By Administrator_India

Capital Sands

Japan’s health ministry has approved dexamethasone, a cheap and widely used steroid, as a second treatment of COVID-19 after a trial in Britain showed the drug reduced death rates in hospitalised patients.

The ministry included dexamethasone as an option for treatment along with Gilead Sciences Inc’s antiviral drug remdesivir in a recent revision to its handbook.

Shares of Nichi-Iko Pharmaceutical Co, among those that produce the drug, gained as much as 6.5% in early trade.

In results announced last month, a trial by researchers in the United Kingdom showed dexamethasone as the first drug to save lives of COVID-19 patients in what scientists said was a major breakthrough in the coronavirus pandemic.

The full results of the large randomised clinical trial released last Friday in the New England Journal of Medicine confirmed the benefits for people with advanced or moderate disease.

Related Posts
Japan June exports seen tumbling again, CPI drop to keep deflation fears alive
Japan June exports seen tumbling again, CPI drop to keep deflation fears alive

By Administrator_India Capital Sands Japan's exports likely tumbled at a double-digit pace for the fourth month in a row in Read more

Japanese researchers confirm coronavirus testing in sewers as possible outbreak warning system
A fifth of Chennai people exposed to COVID-19, says Sero survey

By Administrator_India Capital Sands Japanese researchers confirmed the presence of the coronavirus in wastewater plants, a finding that could serve Read more

India reports over 2.35 lakh COVID-19 cases, 871 fatalities
COVID-19 vaccine booster doses

With 2,35,532 people testing positive for the COVID-19 infection in a day, India’s total tally of cases increased to over Read more

Annual Covid-19 vax preferred to frequent boosters, says Pfizer CEO
Annual Covid-19 vax preferred to frequent boosters says Pfizer CEO

Pfizer Inc Chief Executive Albert Bourla has said that an annual Covid-19 vaccine would be preferable to more frequent booster shots Read more

0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x